Advertisement

Clinical Drug Investigation

, Volume 39, Issue 12, pp 1255–1258 | Cite as

Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Centenarians: A Series of Four Cases

  • Yuval Kuntzman
  • Eyal Zimlichman
  • Howard Amital
  • Shmuel TiosanoEmail author
Research Letter
  • 32 Downloads

The increasing life expectancy has resulted in an ever-increasing proportion of the elderly in the general population [1], and it is estimated that the overall proportion of individuals aged 60 years and above will reach 2 billion by 2050. It is to be expected that the prevalence of age-associated disease, such as atrial fibrillation, will rise in parallel [2]. While there is overwhelming evidence that anticoagulation is critical for stroke prevention in patients diagnosed with atrial fibrillation, anticoagulation is reportedly underprescribed in elderly patients [3]. One of the reasons for withholding anticoagulants is a tendency to overestimate the incidence of intracranial hemorrhage. It has been established that the effectiveness of treatment with non-vitamin K antagonist oral anticoagulant (NOAC) agents is not inferior to that of vitamin K antagonists (VKAs) in populations with an average age of 70–73 years [4]. A 2018 observational study on elderly ethnic Chinese (aged 85 years...

Notes

Compliance with Ethical Standards

Ethical Approval

This study was approved by the local Ethics Committee, Sheba Medical Center, Israel (authorization number 4205-17-SMC).

Conflict of interest

Yuval Kuntzman, Eyal Zimlichman, Howard Amital and Shmuel Tiosano declare no conflicts of interest.

Funding

No funding was received for this study.

References

  1. 1.
    Andreotti F, Rocca B, Husted S, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2015;36:3238–49.PubMedGoogle Scholar
  2. 2.
    Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–5.CrossRefGoogle Scholar
  3. 3.
    Taggar JS, Lip GYH. Anticoagulation for elderly patients with atrial fibrillation: not to be neglected. Europace. 2008;10:1–2.CrossRefGoogle Scholar
  4. 4.
    Zarraga IGE, Kron J. Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts. J Am Geriatr Soc. 2013;61:143–50.CrossRefGoogle Scholar
  5. 5.
    Lai C-L, Chen H-M, Liao M-T, Lin T-T. Dabigatran, rivaroxaban, and warfarin in the oldest adults with atrial fibrillation in Taiwan. J Am Geriatr Soc. 2018;66:1567–74.CrossRefGoogle Scholar
  6. 6.
    Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.CrossRefGoogle Scholar
  7. 7.
    Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–9.CrossRefGoogle Scholar
  8. 8.
    Pamukcu B, Lip GYH, Lane DA. Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. Age Ageing. 2010;39:533–5.CrossRefGoogle Scholar
  9. 9.
    Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366:864–6.CrossRefGoogle Scholar
  10. 10.
    Sardar P, Chatterjee S, Chaudhari S, Lip GYH. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014;62:857–64.CrossRefGoogle Scholar
  11. 11.
    Mansour R, Azrielant S, Watad A, et al. Venous thromboembolism events among RA patients. Mediterr J Rheumatol. 2019;30:13–8.CrossRefGoogle Scholar
  12. 12.
    Kreutz R, Schmidt IM, Dräger D, et al. Atrial fibrillation and medication treatment among centenarians: are all very old patients treated the same? Geriatr Gerontol Int. 2018;18:1634–40.CrossRefGoogle Scholar
  13. 13.
    Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17:302–7.CrossRefGoogle Scholar
  14. 14.
    Barbosa M, Menezes FL. Oral anticoagulation in the elderly: new oral anticoagulants-innovative solution for an old problem? Am J Ther. 2019;26:e133–42.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Medicine ‘B’Sheba Medical Center, Tel-HashomerRamat GanIsrael
  2. 2.Zabludowicz Center for Autoimmune DiseasesSheba Medical Center, Tel-HashomerRamat GanIsrael
  3. 3.Sackler Faculty of MedicineTel-Aviv UniversityTel AvivIsrael
  4. 4.ManagementSheba Medical Center, Tel-HashomerRamat GanIsrael

Personalised recommendations